- Investing Ideas
- Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Bora Pharmaceuticals
Market Cap: NT$53.3b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$418.50
7D
9.0%
1Y
-41.1%
Lotus Pharmaceutical
Market Cap: NT$49.5b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$188.50
7D
9.0%
1Y
-14.3%